•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Service Corporation International Announces Schedule For Second Quarter 2026 Earnings Release and Conference Call
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
CEL-SCI Announces Closing of Offering
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
CEL-SCI Corporation Announces Pricing of Offering
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
SERVICE CORPORATION INTERNATIONAL INCREASES SHARE REPURCHASE AUTHORIZATION
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
Telescope Innovations Founder and CTO, Professor Jason Hein, Receives 2026 SCI Canada LeSueur Memorial Award
Service Corp. (SCI) Down 5.9% Since Last Earnings Report: Can It Rebound?
Service Corporation International: Still A 'Buy' For Long-Term Stability
CEL-SCI Reports Fiscal Second Quarter 2026 Results
Service Corporation International (SCI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CEL-SCI Announces Closing of Public Offering
CEL-SCI Corporation Announces Pricing of Public Offering
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
Service Corp Increases Dividend, Reflects Financial Strength
Service Corporation International (SCI) Presents at Oppenheimer 21st Annual Industrial Growth Virtual Conference Transcript
SERVICE CORPORATION INTERNATIONAL INCREASES QUARTERLY CASH DIVIDEND